RPID
RAPID MICRO BIOSYSTEMS, INC.
$1.99
0.00%
$91.9M
No data for this timeframe.
Vol
Market Cap$91.9M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders4 funds
Inst. Value$3.3M
Inst. Activity2 buys / 0 sells
Insider Activity3B / 13S
Insider Net $-$1.1M
SEC Reports4
Press Releases1
Recent Activity
May 29, 2026
Insider
LOWENSTEIN INESE sold 12,787 shares
Director @ $0.00 ($0.00)
May 29, 2026
Insider
LOWENSTEIN INESE sold 12,787 shares
Director @ $0.00 ($0.00)
May 29, 2026
Insider
LOWENSTEIN INESE sold 12,787 shares
Director @ $1.96 ($25.0K)
May 19, 2026
SEC
Rapid Micro Biosystems is conducting a direct offering of 71,607 shares of Class A common stock and accompanying Series
424B5 — Impact 7/10
May 19, 2026
other
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the
May 13, 2026
SEC
Rapid Micro Biosystems reported Q1 2026 revenue of $8.0M (+11% YoY) and a net loss of $14.3M ($-0.31/share), wider than
8-K — Impact 6/10
Apr 8, 2026
SEC
Rapid Micro Biosystems is holding a shareholder vote on a dissident director election following recent executive changes
DEFA14A — Impact 4/10
Inst.
MORGAN STANLEY — ADD
31,389 shares ($91.0K)
Price Targets
$6.67
+254.6% upside
Strong Buy
Current $1.88
Low $5.00
Median $7.00
High $8.00
3 analysts
$5.00
$8.00
Analyst Ratings
3Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 29, 2026 | Keybanc | MAINTAIN | Overweight → Overweight |
| May 22, 2026 | Lake Street | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.24 ▼ -4.3% | $-0.26 — $-0.23 | 10% YoY | 3 |
| Next Q | $-0.20 ▲ +9.1% | $-0.21 — $-0.19 | 23% YoY | 3 |
| Current FY | $-0.93 ▼ -0.7% | $-0.94 — $-0.91 | 11% YoY | 3 |
| Next FY | $-0.79 ▲ +4.0% | $-0.88 — $-0.74 | 15% YoY | 3 |
Latest Reports
BEARISH
424B5
7/10
Rapid Micro Biosystems is conducting a direct offering of 71,607 shares of Class A common stock and accompanying Series
May 19, 2026
BEARISH
8-K
6/10
Rapid Micro Biosystems reported Q1 2026 revenue of $8.0M (+11% YoY) and a net loss of $14.3M ($-0.31/share), wider than
May 13, 2026
MIXED
Press
6/10
Rapid Micro Biosystems reported strong revenue growth for Q4 and full-year 2025, with Q4 revenue up 37% YoY to $11.3 mil
Mar 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $2.8M | — |
| RENAISSANCE TECHNOLOGIES LLC | $335.3K | TRIM |
| MORGAN STANLEY | $91.0K | ADD |
| BANK OF AMERICA CORP | $37.5K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | LOWENSTEIN INESE | A | $0.00 |
| May 29, 2026 | LOWENSTEIN INESE | A | $0.00 |
| May 29, 2026 | LOWENSTEIN INESE | A | $25.0K |
| May 29, 2026 | PEI MELINDA | A | $0.00 |
| May 29, 2026 | PEI MELINDA | A | $0.00 |
4 institutional holders with $3.3M total value (1,138,726 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 978,781 | $2.8M | 86.0% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 115,627 | $335.3K | 10.2% | TRIM -39.6% |
| 3 | MORGAN STANLEY | 31,389 | $91.0K | 2.8% | ADD +52.7% |
| 4 | BANK OF AMERICA CORP /DE/ | 12,929 | $37.5K | 1.1% | DOUBLED +86093.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 20,550 | 31,389 | +52.7% | $91.0K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 15 | 12,929 | +86093.3% | $37.5K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 36,223 | 20,550 | -43.3% | $68.6K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 8,693 | 290 | -96.7% | $969.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 177 | 15 | -91.5% | $50.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 19,565 | 36,223 | +85.1% | $125.0K | 2025-Q2 |
| UBS Group AG | DOUBLED | 21 | 8,693 | +41295.2% | $30.0K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 183,087 | 110,587 | -39.6% | $291.9K | 2025-Q1 |
| MORGAN STANLEY | ADD | 10,108 | 19,565 | +93.6% | $51.7K | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 72,024 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 82,145 | 183,087 | +122.9% | $164.8K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEW | — | 72,024 | — | $64.8K | 2024-Q4 |
11 unique insiders with 16 transactions. Net insider value: -$1.1M ($0.00 bought, $1.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | LOWENSTEIN INESE | Director | A | 12,787 | $0.00 | $0.00 |
| May 29, 2026 | LOWENSTEIN INESE | Director | A | 12,787 | $0.00 | $0.00 |
| May 29, 2026 | LOWENSTEIN INESE | Director | A | 12,787 | $1.96 | $25.0K |
| May 29, 2026 | PEI MELINDA LITHERLAND | Director | A | 12,787 | $0.00 | $0.00 |
| May 29, 2026 | PEI MELINDA LITHERLAND | Director | A | 12,787 | $0.00 | $0.00 |
| May 29, 2026 | PEI MELINDA LITHERLAND | Director | A | 12,787 | $1.96 | $25.0K |
| May 29, 2026 | Malloy Kirk | Director | A | 12,787 | $0.00 | $0.00 |
| May 29, 2026 | Malloy Kirk | Director | A | 12,787 | $0.00 | $0.00 |
| May 29, 2026 | Malloy Kirk | Director | A | 12,787 | $1.96 | $25.0K |
| May 29, 2026 | WIRTJES SEAN M | CHIEF FINANCIAL OFFICER | A | 12,787 | $0.00 | $0.00 |
| May 29, 2026 | WIRTJES SEAN M | CHIEF FINANCIAL OFFICER | A | 12,787 | $0.00 | $0.00 |
| May 29, 2026 | WIRTJES SEAN M | CHIEF FINANCIAL OFFICER | A | 12,787 | $1.96 | $25.0K |
| May 29, 2026 | Spignesi Robert G. Jr. | PRESIDENT AND CEO | A | 12,787 | $0.00 | $0.00 |
| May 29, 2026 | Spignesi Robert G. Jr. | PRESIDENT AND CEO | A | 12,787 | $0.00 | $0.00 |
| May 29, 2026 | Spignesi Robert G. Jr. | PRESIDENT AND CEO | A | 12,787 | $1.96 | $25.0K |
| May 21, 2026 | Bika Dafni | Director | A | 19,300 | $0.00 | $0.00 |
| May 21, 2026 | Bika Dafni | Director | A | 38,700 | $0.00 | $0.00 |
| May 21, 2026 | PEI MELINDA LITHERLAND | Director | A | 19,300 | $0.00 | $0.00 |
| May 21, 2026 | Kollender Richard S | Director | A | 19,300 | $0.00 | $0.00 |
| May 21, 2026 | Kollender Richard S | Director | A | 38,700 | $0.00 | $0.00 |
| May 21, 2026 | PEI MELINDA LITHERLAND | Director | A | 38,700 | $0.00 | $0.00 |
| May 21, 2026 | Malloy Kirk | Director | A | 19,300 | $0.00 | $0.00 |
| May 21, 2026 | Malloy Kirk | Director | A | 38,700 | $0.00 | $0.00 |
| May 21, 2026 | LOWENSTEIN INESE | Director | A | 19,300 | $0.00 | $0.00 |
| May 21, 2026 | LOWENSTEIN INESE | Director | A | 38,700 | $0.00 | $0.00 |
| May 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | BUY | 1,463,000 | $0.00 | $0.00 |
| May 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | BUY | 1,463,000 | $0.00 | $0.00 |
| May 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | BUY | 1,463,000 | $0.00 | $0.00 |
| Mar 11, 2026 | Wilson John J. Addington | CHIEF OPERATING OFFICER | SELL | 9,603 | $4.32 | $41.5K |
| Mar 11, 2026 | WIRTJES SEAN M | CHIEF FINANCIAL OFFICER | SELL | 7,480 | $4.32 | $32.3K |
| Mar 10, 2026 | Spignesi Robert G. Jr. | PRESIDENT AND CEO | SELL | 17,922 | $4.11 | $73.7K |
| Feb 27, 2026 | RICCIARDI NATALE S | Director | M | 842 | $0.7500 | $631.50 |
| Feb 27, 2026 | RICCIARDI NATALE S | Director | M | 842 | $0.7500 | $631.50 |
| Feb 20, 2026 | Wilson John J. Addington | CHIEF OPERATING OFFICER | SELL | 5,403 | $3.92 | $21.2K |
| Feb 20, 2026 | WIRTJES SEAN M | CHIEF FINANCIAL OFFICER | SELL | 17,254 | $3.92 | $67.7K |
| Feb 19, 2026 | Spignesi Robert G. Jr. | PRESIDENT AND CEO | SELL | 38,327 | $3.89 | $148.9K |
| Feb 11, 2026 | Wilson John J. Addington | CHIEF OPERATING OFFICER | A | 147,000 | $0.00 | $0.00 |
| Feb 11, 2026 | Wilson John J. Addington | CHIEF OPERATING OFFICER | A | 74,000 | $0.00 | $0.00 |
| Feb 11, 2026 | Spignesi Robert G. Jr. | PRESIDENT AND CEO | A | 264,000 | $0.00 | $0.00 |
| Feb 11, 2026 | Spignesi Robert G. Jr. | PRESIDENT AND CEO | A | 528,000 | $0.00 | $0.00 |
| Feb 11, 2026 | WIRTJES SEAN M | CHIEF FINANCIAL OFFICER | A | 97,000 | $0.00 | $0.00 |
| Feb 11, 2026 | WIRTJES SEAN M | CHIEF FINANCIAL OFFICER | A | 193,000 | $0.00 | $0.00 |
| Feb 9, 2026 | Spignesi Robert G. Jr. | PRESIDENT AND CEO | SELL | 12,840 | $3.78 | $48.6K |
| Feb 9, 2026 | WIRTJES SEAN M | CHIEF FINANCIAL OFFICER | SELL | 6,027 | $3.78 | $22.8K |
| Feb 9, 2026 | Wilson John J. Addington | CHIEF OPERATING OFFICER | SELL | 4,610 | $3.78 | $17.4K |
| Feb 4, 2026 | Longitude Capital Partners II, LLC | 10%+ Owner | SELL | 49,000 | $3.88 | $190.1K |
| Feb 3, 2026 | Longitude Capital Partners II, LLC | 10%+ Owner | SELL | 27,500 | $4.24 | $116.6K |
| Feb 2, 2026 | Longitude Capital Partners II, LLC | 10%+ Owner | SELL | 27,500 | $4.25 | $116.8K |
| Jan 30, 2026 | Longitude Capital Partners II, LLC | 10%+ Owner | SELL | 46,000 | $4.54 | $209.0K |
| Jan 23, 2026 | Longitude Capital Partners II, LLC | 10%+ Owner | X | 629,032 | $0.0500 | $31.5K |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 5.3/10.
BEARISH
424B5
7/10
Rapid Micro Biosystems is conducting a direct offering of 71,607 shares of Class A common stock and
May 19, 2026
BEARISH
8-K
6/10
Rapid Micro Biosystems reported Q1 2026 revenue of $8.0M (+11% YoY) and a net loss of $14.3M ($-0.31
May 13, 2026
NEUTRAL
DEFA14A
4/10
Rapid Micro Biosystems is holding a shareholder vote on a dissident director election following rece
Apr 8, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing includes I
Mar 12, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 3 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.67 mean target
+254.6% upside
Strong Buy (1.00)
$5.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $1.88 |
| Target Low | $5.00 |
| Target Mean | $6.67 |
| Target Median | $7.00 |
| Target High | $8.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.24 | $-0.26 | $-0.23 | 9.9% | -4.3% | 1↑ 2↓ | $0.0B | 8.4% | 3 |
| Next Q 2026-09-30 |
$-0.20 | $-0.21 | $-0.19 | 23.1% | +9.1% | 3↑ 0↓ | $0.0B | 30.4% | 3 |
| Current FY 2026-12-31 |
$-0.93 | $-0.94 | $-0.91 | 11.4% | -0.7% | 1↑ 2↓ | $0.0B | 17.0% | 3 |
| Next FY 2027-12-31 |
$-0.79 | $-0.88 | $-0.74 | 15.0% | +4.0% | 2↑ 0↓ | $0.0B | 18.5% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.243 | |
| 7d ago | $-0.253 | +0.010 |
| 30d ago | $-0.233 | -0.010 |
| 60d ago | $-0.225 | -0.018 |
| 90d ago | $-0.205 | -0.038 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 29, 2026 | Keybanc | MAINTAIN | Overweight | Overweight |
| May 22, 2026 | Lake Street | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
other
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in th
May 13, 2026
earnings
Rapid Micro Biosystems Reports First Quarter 2026 Financial Results
<p align="justify">LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative lif
May 13, 2026
earnings_calendar
RPID Q1 2026 Earnings Scheduled — 2026-05-13
May 7, 2026
earnings_calendar
RPID Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
earnings
Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026
<p align="justify">LEXINGTON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative lif
Mar 12, 2026
earnings
Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
<p align="justify">LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative l
Mar 12, 2026
other
Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform
Companies deepen partnership to advance automated, integrated microbiology quality control <pre>Companies deepen partnership to advance automated, int
Mar 12, 2026
earnings_calendar
RPID Q4 2025 Earnings After Market Close — 2026-03-12
Mar 10, 2026
other
Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum
<p align="justify">LEXINGTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative l
Feb 27, 2026
earnings_calendar
RPID Q4 2025 Earnings After Market Close — 2026-02-27